🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.
Presentation (Oral):
Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”
Presenter: Dr. Lloyd L. Tran (CEO)
Date & Time: June 20, 2025 – oral session (specific time TBD at conference)
Poster:
Title: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial Results of NA‑831 for AD and NA‑931 for Obesity.”
Also: Sunday general poster session (details to follow)
NA‑931 is notable for being a first-in-class oral quadruple agonist targeting IGF‑1, GLP‑1, GIP, and glucagon receptors, with both oral presentation and poster detailing both obesity and Alzheimer’s links
💊 RGT‑075 – Regor Therapeutics Group
Poster Presentation:
Title: “First Report on the Small Molecule Oral GLP‑1 Receptor Agonist RGT‑075 in Obesity—A Randomized, Placebo‑Controlled Phase 2a Proof‑of‑Concept Twelve‑Week Study.”
Session: Sunday, June 22, 12:30–13:30 CDT – Poster #785P 12‑B
📌 ASC30 – Ascletis Pharma Inc.
Poster:
Title: “ASC30, an Oral GLP‑1R Biased Small Molecule Agonist in Participants with Obesity—A First‑in‑Human Single Ascending Dose Study.”
Session: Sunday, June 22, 12:30–13:30 CDT – General Poster Session, Poster #750‑P
📌 ASC47 – Ascletis Pharma Inc.
Poster:
Title: “ASC47, a Muscle‑Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model.”
Session: Sunday, June 22, 12:30–13:30 CDT – General Poster Session, Poster #847‑P
RGT‑075 and ASC30/ASC47 are small-molecule oral agents in Phase 2 or preclinical stages, each with a single poster session on Sunday June 22 at 12:30 CDT .
🧬 CT‑388 – Roche
Poster Presentation
Title: “Effect of CT‑388, a Signal‑Biased Dual GLP‑1/GIP Receptor Agonist, on Liver‑Related MRI Parameters in Patients With Obesity.”
Presenter: Alexandra Steinberg
Session details: ADA 2025 poster session (exact day/time TBD)
CT‑388 by Roche is a dual GLP‑1/GIP agonist with proprietary “signal-biased” mechanism; it’s being highlighted for its effects on liver MRI markers in obesity
💉 MariTide – Amgen
Oral Symposium
Title: “Phase 2 Trial Results and Pharmacokinetics of MariTide in Obesity.”
Date & Time: June 23, 2025 (part of ADA symposium)
MariTide (Amgen) is expected to bring new Phase 2 efficacy and pharmacokinetic data at the June 23 symposium — this includes dosing frequency insights (possibly monthly or less often)
🧠 Investigational dual-GLP‑1/GIP agonist – Regeneron
Strategic Session/Poster
Title: Focused on Regeneron’s newly in‑licensed dual GLP‑1/GIP agonist candidate (name not publicly disclosed yet)
Timing: Likely during ADA sessions—exact details TBD; company announcement June 2, 2025
Regeneron recently in-licensed a novel dual agonist, with ADA presentations anticipated—details remain under wraps at this stage